Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial

Posted on by

Lancet Infectious Diseases
Feb 2022 Volume 22 Number 2 p151-296, e41-e65
https://www.thelancet.com/journals/laninf/issue/current

 

Articles
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial
ShengLi Xia, et al.